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Alterations in phenotype and gene expression of adult human aneurysmal
smooth muscle cells by exogenous nitric oxide
Kurt Farrell, Phillip Simmers, Gautam Mahajan, Ludovic Boytard, Andrew Camardo, Jyotsna
Joshi, Anand Ramamurthi, Florence Pinet, Chandrasekhar R. Kothapalli
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A B S T R A C T

Abdominal aortic aneurysms (AAA) are characterized by matrix remodeling, elastin degradation, absence ofT
nitric oxide (NO) signaling, and inﬂammation, inﬂuencing smooth muscle cell (SMC) phenotype and gene expression. Little is known about the biomolecular release and intrinsic biomechanics of human AAA-SMCs. NO
delivery could be an attractive therapeutic strategy to restore lost functionality of AAA-SMCs by inhibiting
inﬂammation and cell stiﬀening. We aim to establish the diﬀerences in phenotype and gene expression of adult
human AAA-SMCs from healthy SMCs. Based on our previous study which showed beneﬁts of optimal NO dosage
delivered via S-Nitrosoglutathione (GSNO) to healthy aortic SMCs, we tested whether such beneﬁts would occur
in AAA-SMCs. The mRNA expression of three genes involved in matrix degradation (ACE, ADAMTS5 and
ADAMTS8) was signiﬁcantly downregulated in AAA-SMCs. Total protein and glycosaminoglycans synthesis were
higher in AAA-SMCs than healthy-SMCs (p < 0.05 for AAA-vs. healthy- SMC cultures) and was enhanced by
GSNO and 3D cultures (p < 0.05 for 3D vs. 2D cultures; p < 0.05 for GSNO vs. non-GSNO cases). Elastin gene
expression, synthesis and deposition, desmosine crosslinker levels, and lysyl oxidase (LOX) functional activity
were lower, while cell proliferation, iNOS, LOX and ﬁbrillin-1 gene expressions were higher in AAA-SMCs
(p < 0.05 between respective cases), with diﬀerential beneﬁts from GSNO exposure. GSNO and 3D cultures
reduced MMPs −2, −9, and increased TIMP-1 release in AAA-SMC cultures (p < 0.05 for GSNO vs. non-GSNO
cultures). AAA-SMCs were inherently stiﬀer and had smoother surface than healthy SMCs (p < 0.01 in both
cases), but GSNO reduced stiﬀness (~25%; p < 0.01) and increased roughness (p < 0.05) of both cell types. In
conclusion, exogenously-delivered NO oﬀers an attractive strategy by providing therapeutic beneﬁts to AAASMCs.

1. Introduction
Chronic vascular pathological conditions (e.g., hypertension,
atherosclerosis, trauma, infection) promote localized release of proteinases and enzymes which break down the intact extracellular matrix
(ECM; e.g., elastin, glycosaminoglycans (GAGs)) within the adult abdominal aortic walls [1,2]. Unfortunately, the major cell types in aorta,
i.e., smooth muscle cells (SMCs) and adventitial ﬁbroblasts, are limited
in their ability to repair, replace or regenerate the degraded vascular
matrix, which often results in progressive weakening and burgeoning of
blood vessel diameter (> 50% increase relative to healthy vessel) – a
condition clinically termed as abdominal aortic aneurysm (AAA). AAAs

are also typically characterized by the presence of innate and adaptive
immune cells (e.g., macrophages, T-cells, neutrophils, lymphocytes)
which release abnormal levels of cytokines and matrix metalloproteinases (MMPs) to exacerbate the breakdown of elastic ﬁbers and other
matrix proteins [3,4]. This, in turn, disrupts the signaling between
elastic ﬁbers and SMCs, promotes SMC apoptosis, and weakens elasticity in blood vessel walls, to permanently alter the mechanical properties and native microenvironment of the vessel wall [5,6].
Among the major ECM components native to blood vessels, collagen, GAGs and elastin play an important role in regulating cell adhesion, anchoring, proliferation, and migration [4,7]. They also regulate blood vessel homeostasis by supporting axial and circumferential
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loadings and conferring anti-thrombogenic properties [8]. These ECM
molecules are synthesized, crosslinked, and deposited as mature matrix
ﬁbers by SMCs and adventitial ﬁbroblasts within the aorta. While the
turnover of collagens and GAGs is maintained even through adolescence, elastic matrix ﬁber deposition primarily occurs only during developmental stages and preserved throughout the adult life (elastin
half-life is ~74 years) [9]. Since healthy elastic ﬁbers play critical
biochemical and biomechanical roles in maintaining vessel homeostasis, abnormalities in elastin formation due to genetic defects or
elastin degradation due to diseases could result in peptides formation,
which obfuscates the beneﬁcial role of intact elastic ﬁbers [10,11].
Given the limitations of existing surgical (e.g., endovascular aneurysm repair, open surgery), pharmacological (e.g., anti-inﬂammation
agents, beta-blockers, statins) and preservation (e.g., MMPs inhibition,
TIMPs delivery, elastases suppression) interventions for comprehensive
AAA treatment [9,12–15], ECM (speciﬁcally elastin) repair and regeneration approaches focusing on tissue-engineered grafts, stem cells,
3D scaﬀolds, bimolecular cues, biomechanics, and their combinations,
are being explored [16,17]. While the phenotype and gene expression
of ECM proteins synthesized by healthy Hu-SMCs has been reported
[18–21], similar outcomes from their AAA-counterparts are unknown.
Speciﬁcally, the baseline levels of matrix proteins synthesized and deposited by human AAA-SMCs, changes in their phenotype and gene
expression, the cytokines and chemokines released, their stiﬀness levels, and the responses to exogenous biomolecular cues, remains unexplored. Such information is critical for understanding the disease
etiology and identify eﬀective pharmacological, tissue engineering and
regenerative medicine strategies to repair and regenerate elastin in AAA
vessels.
We have recently reported on the beneﬁts of delivering exogenous
nitric oxide (NO) cues via S-nitrosoglutathione (GSNO), to cell proliferation and ECM deposition by adult human aortic SMCs (Hu-SMCs)
within 3D biomimetic cocultures with adult human endothelial cells
(Hu-ECs) [22]. Such NO delivery from GSNO was also shown to suppress cell proliferation and stimulate mRNA expression and synthesis of
tropoelastin and lysyl oxidase (LOX) in chick aortic SMC cultures [23].
Physiologically, NO is produced from L-arginine and oxygen by endothelium nitric oxide synthases (eNOS) [24], and exogenous NO
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exposure inhibits eNOS activity [25,26] and induces S-nitrosylation of
cysteine residues [27]. NO donors and eNOS gene transfer were shown
to inhibit SMC proliferation in vitro, resulting in a delay in cell cycle
progression but not apoptosis [28–30]. NO delivered from the donor
compounds such as diethylenetriamine NONOate and S-nitro-N-acetylpenicillamine inhibited elastase release and activity, and matrix remodeling by porcine pulmonary artery SMCs, by repressing ERK
phosphorylation [31,32]. These studies attest to the role of NO donors
and NOS in promoting elastogenesis at transcriptional- & translationallevels, and attenuating inﬂammation within diseased aortic tissues.
This study is based on the hypothesis that exogenous NO delivery to
AAA-SMCs will inhibit inﬂammatory markers release, suppress cell
proliferation, promote elastic matrix synthesis, and enhance healthy
and contractile phenotype, thereby providing an attractive therapeutic
strategy to restore the lost functionality of AAA-SMCs and improve
vascular tone. We ﬁrst investigated the changes in transcription levels
of AAA-SMC genes, involved in the pathological progression of this
disease. Next, we assessed the in vitro baseline levels of cell proliferation, phenotypic and genetic expression, ECM and biomolecular
(elastin, sulfated glycosaminoglycans (sGAGs), hyaluronan (HA), LOX,
desmosine, inducible nitric oxide synthase - iNOS) synthesis and deposition, release of cytokines/chemokines/MMPs/TIMPs, and biomechanical characteristics of human AAA-SMCs. Similar outcomes from
healthy Hu-SMCs were assessed under identical culture conditions for
comparison. Finally, the response of AAA-SMCs to exogenously-delivered NO cues was evaluated and compared to their healthy counterparts, to investigate the utility of delivering exogenous NO for AAA
treatment.
2. Materials and methods
2.1. Population study
LILAS was a case-control study that enrolled 42 men, some with
AAA, who needed a vascular surgery or endovascular treatment at the
Lille University Hospital Centre (Lille, France) between September
2003 and July 2005 [33]. Case patients were considered eligible if the
AAA diameter, measured by abdominal ultrasound exceeded 50 mm, or
Fig. 1. (A) A sample AAA tissue (n = 20 patients)
used for SMC cultures. Representative phase-contrast
microscopy of SMCs obtained by explant from
human AAA biopsies. Western blot analysis of SMC
for ﬁbronectin, meta-vinculin (160 kDa), vinculin
(116 kDa) and α-smooth muscle actin (α-SMA). Scale
bar: 100 μm. (B) mRNA expression ratio of genes
(2−dCt; normalized to house-keeping genes) in SMCs
derived from AAA (n = 12) patients, potentially involved in matrix degrading processes in AAA, as
determined by RT-PCR.

if it had increased more than 10 mm during the past six months and
required initial surgical treatment (Supplementary Table 1). The study
conformed to the principles outlined in the Declaration of Helsinki,
ethics committee of the Lille University Hospital Centre (France) approved the study, and each patient provided written informed consent.
Clinical data items were presented as mean ± SD, and frequencies
with proportions as appropriate. Statistical signiﬁcance was assigned at
p < 0.05.
2.2. Isolation of human AAA-SMCs
Aortic samples (Fig. 1A) were obtained for 20 of the 24 AAA patients and SMCs were isolated from all the 20 AAA tissue samples. Individual cultures of AAA-SMCs were established for each patient by
dissection of a residual segment of abdominal aorta and then cutting
out the media into 1–2 cu.mm pieces and culturing them on type 1
collagen coated dishes (rat tail-derived, BD Biosciences, France) in
medium 231 supplemented with smooth muscle growth supplement
(Cascade Biologics, France) and antibiotics (50 μg/mL streptomycin, 50
U/mL penicillin; Sigma-Aldrich). SMCs were characterized by Western
blot analysis. Twenty microgram fractions of cell lysates were separated
by SDS-PAGE (9% polyacrylamide), transferred to Hybond C membranes (GE Healthcare, France) and blotted with antibodies against αsmooth muscle actin (α-SMA) (1A4, Dako, 1:5000), ﬁbronectin (E3A,
Sigma-Aldrich, 1:3000), and vinculin/meta-vinculin (hVIN-1, SigmaAldrich, 1:400). The blots were subsequently washed in PBS-Tween 20
and incubated with appropriate secondary antibodies (peroxidaseconjugated anti-mouse IgG, GE Healthcare) at a dilution of 1:5000. The
blots were then washed three times in PBS-Tween 20 for 15 min, incubated with enhanced chemiluminescence reagents (GE Healthcare),
and exposed to a radiographic ﬁlm and scanned with an Imagescanner®
(GE Healthcare). AAA-SMCs were subsequently passaged with Medium
231 (Life Technologies).
2.3. Transcriptomic analysis of human AAA-SMCs
Changes in SMCs were validated for selected genes with qRT-PCR.
RNA samples isolated from SMCs were converted to cDNA with an in
vitro reverse transcription reaction. These cDNA were used as templates
for Taqman qRT-PCR with ABI Assays-on-Demand on an ABI Prism
7900 sequence detection system. The speciﬁc assays were designed by
TaqMan® Gene Expression Assays (Applied Biosystems) and used Hs
00199841-m1 (ADAMTS 5), Hs 00199836-m1 (ADAMTS 8), Hs
00166915-m1 (renin), Hs 00174179-m1 (ACE1), and Hs 00377632-m1
(L-cathepsin). All samples were run in triplicate, with GADPH
(Hs99999905_m1) and Cyclophilin A (Hs99999904_m1) as internal
controls to normalize transcript abundance (2−dCt method). Triplicates
were averaged to calculate an expression value for each sample.

microscope equipped with Hamamatsu camera and image acquisition
software. At least ten images per cell type were processed using ImageJ
(NIH) to quantify the perimeter and area of each cell type.
Two sets of cultures were performed in parallel. 3D collagen gels
were prepared by mixing collagen stock solution (type 1, rat-tail derived, BD Biosciences, Bedford, MA, USA) with a mixture of 10 × PBS,
1 M NaOH and deionized water. For 3D cultures, SMCs were mixed in
collagen gels at a density of 104 cells per well in 48-well plates. The
cultures were placed in a humidiﬁed incubator (37 °C, 30 min) to
polymerize the collagen gels. For 2D cultures, collagen-coated 24-well
tissue culture plastic plates were seeded with 104 cells per well. Both
healthy- and AAA- SMCs were plated from passages 4–6. GSNO dose
used in this study was identiﬁed from our previous study [22] where a
range of GSNO doses were tested to evaluate their eﬀects on ECM
synthesis and deposition. Media was changed once every two days and
the spent medium was pooled over the 21-day culture and stored at
−20 °C for further biochemical analyses. Similarly, cell matrix layers at
the end of 21 days were trypsinized and processed for biochemical
assays.

2.5. Biochemical assays
At the end of 21 days, the amounts of various protein types released
into the pooled media or deposited within cell matrix of 2D and 3D
cultures were quantiﬁed as detailed earlier [22]. Individual biochemical assays were performed on AAA-SMC cultures to quantify total
protein (BCA Kit Assay; Sigma-Aldrich), elastin (Fastin assay; Accurate
Scientiﬁc Corp, Westbury, NY), sulfated glycosaminoglycans (sGAGs;
Kamiya Biomedical Company, Seattle, WA), and HA (hyaluronan enzyme-linked immunosorbent quantitative assay; Echelon Biosciences
Inc., Salt Lake City, UT) amounts. The protein amounts within cells was
not separated from the total protein quantiﬁed within cell layers. The
non-cellular protein contribution to the BCA assay (from collagen gels
in which the cells were cultured) was accounted by estimating the
protein content in 2 mg/mL collagen gels and collagen-coated 2D cultures without cells, and deducting from the measured total protein
amounts reported in test cases. Although other ECM proteins such as
collagens might be released and deposited by SMCs, their amounts were
not assessed here. SMC proliferation was quantiﬁed using a ﬂuorometric assay detailed earlier [22], to quantify the amount of DNA
Table 1
Baseline characteristics of the study population in AAA group.
AAA: aortic abdominal aneurysm; CAD: coronary artery disease;
MI: myocardial infarction; ACS: acute coronary syndrome;
PTCA: percutaneous transluminal coronary angioplasty. Data
expressed as mean ± SD, where appropriate.
AAA(n = 24)

2.4. Human AAA and healthy aortic SMC cultures
AAA-SMCs derived from one patient (details in Table 1) were investigated further using biochemical and biomechanical analysis to
establish the baseline. Healthy adult abdominal aortic Hu-SMCs were
obtained from Life Technologies Corp. (Carlsbad, CA, USA) and passaged using Medium 231 (ThermoFisher Scientiﬁc, USA). AAA-SMCs
were cultured on 2D collagen-coated (50 μg/mL) substrates or within
3D collagen hydrogels (2 mg/mL; pH ~ 7.2). Results from 2D substrates
will help establish the baseline values, while cultures in 3D gels will
provide more physiological-mimic microenvironment. Cells were cultured for 21 days in SMC media, containing 100 nM GSNO (Sigma,
Saint-Louis, MO, USA), a NO donor. Control cultures received no GSNO
(termed 0 nM). The culture media contained recombinant human insulin-like growth factor-I (2 μg/mL) and glucose (D-Glucose; levels unknown). Healthy and AAA-derived SMCs were imaged at random locations during passaging using a Zeiss Axiovert A1 ﬂuorescence

Age, years
Male gender, %
Anthropometric data
Weight, kg
Height, cm
Body mass index, kg/m2
Cardiovascular risk factors, n (%)
Current smoking
Past smoking
Hypercholesterolemia
Hypertension
Diabetes mellitus
Familial history of CAD
Personal history of CAD, n (%) Stable
Angina
MI or ACS
Coronary artery bypass
PTCA
History of stroke, n (%)

68.0 ± 6.1
24 (100)
82.9 ± 11.6
173.8 ± 5.4
27.4 ± 3.7
4 (17)
17 (71)
14 (58)
15 (63)
4 (17)
4 (17)
2
7
1
4
0

(8)
(29)
(4)
(17)

synthesized over the 21 days. Similarly, LOX functional activity was
quantiﬁed using a ﬂuorometric assay (AmplexRed® Assay; Molecular
Probes, Eugene, OR).
2.6. Desmosine bioassay
The amount of desmosine produced and released by AAA-SMCs and
healthy SMCs into the pooled media was quantiﬁed using a sandwich
enzyme immunoassay technique (Human Desmosine ELISA Kit;
MyBioSource, Inc., San Diego, CA). The desmosine bioassay has a detection range of 0.1–10 ng/mL and a sensitivity of 0.039 ng/mL. Brieﬂy,
aliquots of samples and standards were incubated in a 48-strip-well precoated with desmosine-speciﬁc antibody, and the bound desmosine was
serially-tagged with biotin-conjugated DES-speciﬁc antibody and
avidin-conjugated horseradish peroxidase, with intermediate washings
after every step. Finally, desmosine amounts in each sample were assessed calorimetrically based on the intensity of color generated within
a substrate solution in proportion to the respective DES amounts.
2.7. Real-time PCR analysis of SMCs
For RT-PCR analysis, AAA-SMCs and healthy SMCs were cultured in
parallel on 2D collagen-coated substrates or within 3D collagen gels and
exposed to 100 nM GSNO for 5 days to induce changes in gene expression, and GSNO-free cultures served as controls. Total RNA was
extracted from SMCs using RNAqueous®-Micro total RNA isolation kit
(Life technologies) according to the manufacturer's instructions. The
RNA concentration of each sample was determined using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientiﬁc, Wilmington, DE). The
RNA was reverse-transcribed to cDNA using the high-capacity cDNA
reverse transcription kit with RNase inhibitor (Life Technologies) according to manufacturer's instructions. Gene expression in SMCs was
quantiﬁed using TaqMan® gene expression assays (Applied Biosystems),
and TaqMan® Gene expression master mix for each target using the ABI
7500 Real-time PCR System (Applied Biosystems, Forest City CA) limited to only 40 cycles. The following genes (details in Supplementary
Table 2) were analyzed: lysyl oxidase (LOX, Assay ID:
Hs00942480_m1), elastin (ELN, Assay ID: Hs00355783_m1), ﬁbrillin 1
(FBN1, Assay ID: Hs00171191_m1), and inducible nitric oxide synthase
2 (NOS2, Assay ID: Hs01075529_m1). To identify relative diﬀerences in
the levels of target genes, gene expression in AAA-SMCs was normalized
to endogenous reference gene (18S, Assay ID: 4319413E) and further to
corresponding expression in healthy SMCs, using the ΔΔCt method.
2.8. Cytokine/chemokine assays
Cytokine, chemokine, TIMP and MMP analyses were performed
using Discovery Assays® (Eve Technologies, Alberta Canada), from 2D
or 3D cultures of AAA-SMCs and healthy SMCs. Brieﬂy, cell culture
supernatants were collected from each well after 24 h, spun down at
3000 g for 5 min, and stored at −20 °C. The supernatants were then
processed using multiplexing LASER bead technology and processed on
a dual-laser ﬂow-cytometry system (Bio-Plex 200). The technology
works by utilizing diﬀerent combinations of red and infrared ﬂuorophore beads conjugated to speciﬁc antibodies targeted to the cytokine
or chemokine of choice and read using a ﬂow-cytometry based system.
The quantity of the speciﬁc analyte generated was based oﬀ a series of
standards set forth by the company. The assays performed include
human focused 11-plex, human MMP 9-plex and TIMP 4-plex, to
quantify the following analytes: GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12 (p70), MCP-1, TNF-α, MMPs-1, 2, 3, 7, 8, 9, 10, 12,
13, and TIMPs-2, 3, 4.
2.9. Western blot analysis of iNOS

iNOS expression within healthy and AAA-SMCs, in both 2D and 3D

cultures, in the presence or absence of GSNO, was semi-quantitatively
evaluated using Western blot analysis as we detailed elsewhere [22]. To
optimize loading sample volumes for SDS/PAGE Western blot, cell
pellets from respective cultures were assayed using a DC protein assay
kit (Bio-Rad Labs). The protein bands were detected using a primary
polyclonal antibody for the iNOS protein (Abcam), using SMC-alpha
actin (Abcam) as the loading control, and the bands were visualized
using chemiluminescence method and quantiﬁed using ImageJ.
2.10. TIMP-1 assay
TIMP-1 amounts released by healthy and AAA-SMCs into the pooled
media, in the presence or absence of GSNO, were quantiﬁed using
Human TIMP-1 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN).
Spent media (supernates) from the cell cultures in 2D or 3D were
pooled and stored at −20 °C and loaded onto a 96-well polystyrene
microplate coated with a monoclonal antibody speciﬁc for human
TIMP-1. Post-incubation (2 h, RT) on a horizontal orbital shaker, the
bound proteins were incubated with human TIMP-1 speciﬁc horseradish peroxidase-linked polyclonal antibody (1 h, RT), exposed to a
chromogen solution containing tetramethylbenzidine for (30 min, RT,
dark), and the reaction was stopped with 2 N sulfuric acid. Final solutions were measured using Epoch BioTek microplate spectrophotometer
with absorbance at 450 nm. This assay has a range of 0.2–10 ng/mL in
cell culture supernates, with a sensitivity of 0.08 ng/mL.
2.11. Immunoﬂuorescence labeling of cell layers
AAA-SMCs were cultured on glass chamber slides (104 cells/well)
for 21 days in the presence or absence of 100 nM GSNO, and the cell
layers were ﬁxed in cold methanol, washed with PBS, blocked with PBS
containing 5% v/v goat serum (ThermoFisher Scientiﬁc) and immunolabeled with rabbit anti-human polyclonal antibodies against
elastin (1:100 v/v dilution, Abcam), ﬁbrillin-1 (1:100 v/v dilution,
Bioss Antibodies), ﬁbulin-4 (1:100 v/v dilution, Santa Cruz
Biotechnology), and ﬁbulin-5 (1:100 v/v dilution, Santa Cruz
Biotechnology). Cell layers were washed with PBS and labeled with
Alexaﬂuor 633 goat anti-rabbit secondary antibody; 1:1000 dilution,
ThermoFisher Scientiﬁc). The cell layers were washed with PBS and
mounted with Vectashield containing the nuclear stain 4′,6-Diamidino2-Phenylindole, Dihydrochloride (DAPI; Vector Laboratories,
Burlingame, CA). AAA-SMC layers treated with the secondary probe
alone (no primary antibody) served as negative controls. Cell layers
were imaged with a Leica SP8 confocal microscope (Leica Microsystems
Inc, Buﬀalo Grove, IL).
2.12. Atomic force microscopy (AFM) analysis
Healthy and AAA-SMCs were cultured in 35-mm laminin-coated
petri dishes and maintained at 37 °C throughout live-cell nanoindentation assay, over a 60-min experiment each time, performed
using a MFP-3D-Bio AFM (Asylum Research, Santa Barbara, CA)
mounted on an inverted optical microscope (Nikon Eclipse Ti). Tip-less
AFM cantilevers (model Arrow TL 1, Nano World, nominal spring
constant ~ 0.03 N/m) were modiﬁed by attaching a 4.5 μm polystyrene
bead using epoxy [34]. The spherical bead indenter reduces the possibility of destructive deformation of cell due to smaller local strains
applied [35], compensates for the x-y drift (usually < 1 μm), and
yields higher spatially-averaged measurement with minimal variability,
relative to conventional sharp-tip probes. The actual spring constant
was determined from a force-distance curve and using thermal calibration method in a clean culture dish containing DMEM. Drifting
minimization and thermal/mechanical equilibrium of AFM was
achieved by submerging probe in cell medium for stabilization. For
each experiment, at least 30 cells were randomly selected, indented
between nuclei and cell edges, and 150–200 force curves were obtained

at random locations on each cell in force-volume mode, at a rate of
0.25 Hz with approach/retraction velocity of 2.5 μm/s. Using Hertz's
contact model [F = (4E Rδ 3) /3(1 − μ2 ) ], Young's modulus was determined from these force curves, where F is the indentation force, E is
the Young's modulus, μ is the Poisson's ratio (0.5 for cells), R is radius of
spherical bead attached to cantilever and δ is the indentation depth
(300–400 nm) [35]. The analysis of force-indentation curves was automated using Igor Pro 6.37 software. The indentation data was analyzed assuming cells behave as linearly elastic at small strain regimes.
The mean elastic modulus values were calculated for each cell from the
elastic modulus heat maps generated over randomly-selected
90 × 90 μm2 area, and then averaged across multiple cells for each
culture condition group. From this data, the mean surface roughness
(Ra) of each cell - characterized as the arithmetic mean of the deviations in height from the line mean value, and the root mean square
(Rq), were calculated [36]. Both Ra and Rq were obtained from randomly selected areas (30 × 30 μm2) on the cell membrane. A two-tailed
Student's t-test was applied to all the pairs of samples (untreated-treated
cells) for statistical analysis and p < 0.05 were considered signiﬁcant.
2.13. Statistical analysis
All biochemical data were obtained from three independent repeat
experiments per case (n = 3 wells/case/experiment) and analyzed
using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and diﬀerences deemed signiﬁcant for
p < 0.05. The data were assumed to follow a near-Gaussian distribution in all the cases, and the mean and standard errors were calculated
accordingly.
3. Results
3.1. Patients

Table 1 summarizes the baseline characteristics of the 42 AAA

subjects. One-third of the AAA patients had hypertension, half had
dyslipidemia, 17% had diabetes mellitus, and 29% had family members
who had a history of heart disease (myocardial infarction and/or acute
coronary syndrome). The AAA case patients (n = 24) had a mean
maximal external aortic diameter of 56.1 ± 11.3 mm (range:
46–95 mm). Fewer AAA patients received ACE inhibitor treatment
(21% vs. 44%; Supplementary Table 1). None of the AAA patients took
non-steroidal anti-inﬂammatory drugs (NSAIDs).
3.2. Primary AAA-SMC cultures
SMCs migrated from AAA explants after 10 days and reached conﬂuence in one month. All the cultured AAA-SMCs had the same elongated, spindle-shaped morphology, and at conﬂuence all cultures assumed a hill-and-valley pattern that was maintained throughout
subcultures (Fig. 1A). Protein expression proﬁles determined by Western blot analysis (Fig. 1A) showed that all the cultures from patient
groups expressed α-SMA, vinculin and meta-vinculin, indicating the
presence of diﬀerentiated SMCs. Fibronectin, a component of basement
membrane, was also expressed indicating a proliferative and secretory
SMC phenotype. RT-PCR analysis (Fig. 1B) indicated that mRNA expression of three genes appeared to be signiﬁcantly down-regulated in
SMCs from AAA patients: ACE (angiotensin converting enzyme),
ADAMTS 5 and ADAMTS 8. The plots of individual mRNA expression
for these three genes (normalized to house-keeping genes) shows the
variability, with ADAMTS8 being the most suppressed.
3.3. AAA-SMC proliferation and dimensions
Despite similar morphologies within 2D cultures, the area and
perimeter of AAA-SMCs within 2D cultures were signiﬁcantly higher
compared to their healthy counterparts (Fig. 2A; p < 0.01 in both
cases). The phenotype of AAA-SMCs was conﬁrmed by staining for αactin in monolayer cultures, with more than 98% positive-stained cells.
In general, AAA-SMC proliferation is signiﬁcantly lower in 3D gels

Fig. 2. (A) Representative phase-contrast images of adult healthy Hu-SMCs and AAA-SMCs cultured in this study. Signiﬁcant diﬀerences in average cell area and
perimeter were noted between the two cell types. Data shown represents mean ± standard error in respective cases. Scale bar: 200 μm. (B) Fold increase in AAASMC density within 2D and 3D cultures, in the presence or absence of exogenous 100 nM GSNO. Data shown represents mean ± standard error of cell count after 21
days of culture, normalized to initial seeding density (n = 3/condition). Cell densities were quantiﬁed using a ﬂuorometric assay detailed earlier (C) Fold-changes
(vs. GSNO-free controls). in total protein, elastin, sGAG, and HA, deposited within cell matrix or released into pooled media, by human AAA-SMCs, in 2D and 3D
cultures, in the presence of 100 nM GSNO. The total protein amounts were quantiﬁed using a BCA protein assay, elastin amounts using a Fastin Assay kit, sGAG
amounts using a quantitative dye-binding sGAG assay kit, and HA amounts using a hyaluronan enzyme-linked immunosorbent quantitative assay. Quantitative
results were obtained from cell matrix layers or pooled media after 21 days of culture and normalized to cell count within respective cases (n = 6/condition). Data
were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and diﬀerences deemed signiﬁcant for p < 0.05
between respective cases. Data shown represents mean ± standard error in respective cases. The absolute amounts of each protein per cell were listed in Table 2 for
baseline purposes.

compared to their 2D counterparts (Fig. 2B). Addition of GSNO signiﬁcantly suppressed SMC proliferation in 3D gels with a similar trend
in 2D counterparts.

cultures modestly enhanced matrix elastin yields in the absence and
presence of GSNO (0.5% and 0.8%, respectively). Thus, elastic matrix
yields improved by 10-fold in 3D cultures with the addition of GSNO,
similar in trend to that observed for the total protein amounts.

3.4. Total protein synthesis

3.6. sGAG and HA synthesis
Protein synthesis and release by AAA-SMCs has not been reported
earlier. The total protein synthesized by AAA-SMCs, in 2D and 3D
cultures, in the presence or absence of GSNO, was quantiﬁed as two
separate components (Fig. 2C): protein deposited in the cell matrix
(termed matrix here) and protein released into the pooled media
(termed media here). A signiﬁcant increase in the total protein deposited in cell matrix was observed with GSNO addition, in both 2D
(2.58-fold) and 3D (3.1-fold) cultures. Total protein deposited in cell
matrix within 3D cultures was signiﬁcantly higher than that in 2D
counterparts (p < 0.01), in the presence or absence of GSNO (16.4-fold
and 19.8-fold, respectively). GSNO stimulated signiﬁcant increase in
the total protein released into the pooled spent media in 3D cultures
(p < 0.01 vs. 2D). The amounts of protein in pooled media were at
least two-orders of magnitude higher than in matrix, in all conditions.
This study established the baseline for the total protein amounts released and deposited by adult human AAA-SMCs in 2D and 3D cultures
(actual amounts provided in Table 2), in the absence of any stimulation.
However, less than 2% of total protein produced by AAA-SMCs was
deposited as matrix within cell layers, suggesting that additional approaches are required to coacervate the protein into matrix form.
Compared to healthy SMCs (Table 2; Supplementary Fig. 1), the total
protein deposited within 3D cell layers or released into the spent media
by AAA-SMCs was signiﬁcantly higher (i.e., 2-fold and 19-fold, respectively) even in the absence of GSNO. GSNO stimulated a 7-fold
increase in protein deposition within matrix layers and a 17-fold increase in protein release within pooled media by AAA-SMCs within 3D
cultures, compared to Hu-SMCs (Supplementary Fig. 1).
3.5. Elastin synthesis and deposition
The total elastin synthesized by AAA-SMCs (Fig. 2C; Table 2) was
quantiﬁed as that deposited in the cell layers (i.e., matrix elastin) or
released into the pooled media (i.e., tropoelastin). The beneﬁts of
exogenous NO to elastin deposition in cell matrix appeared to be dependent on the substrate type. Compared to GSNO-free controls, signiﬁcantly higher matrix elastin was deposited within 3D cultures with
GSNO addition, although matrix elastin deposition decreased in 2D
cultures. GSNO stimulated tropoelastin release only within 3D cultures,
although the amounts were two-orders of magnitude higher than matrix
elastin (Table 2).
The matrix elastin yields (ratio of matrix elastin to the total elastin
produced) within 2D AAA-SMCs cultures were 0.4% and 0.08% with 0
and 100 nM GSNO additive-cultures, respectively. However, 3D

Adding GSNO to AAA-SMC cultures increased sGAG deposition in
matrix layers (2.73- and 1.52- fold, respectively) and in pooled media
(2.17- and 1.72- fold, respectively) within 2D and 3D cultures, per cell
(Fig. 2C), although the amounts were two orders of magnitude higher in
pooled media. Compared to 2D cultures, 3D cultures appeared to promote sGAG release into pooled media or deposition within cell layers,
per cell (Table 2). sGAG yield (ratio of matrix sGAG to the total sGAG
produced) within 2D AAA-SMC cultures indicated that matrix yields
were 0.9% and 2.3% in controls and GSNO-additive cultures, respectively. However, 3D cultures did not show any enhancement of matrix
sGAG yields, in the presence or absence of GSNO.
GSNO addition modestly increased HA deposition in cell matrix per
cell in both 2D and 3D cultures (1.41- and 1.35- fold, respectively;
Fig. 2C), with similar increases in HA release into the pooled media.
When AAA-SMCs were cultured in 2D, the matrix HA yields (ratio of HA
deposited in matrix to the total HA produced) were 1.6% and 1.7%
within controls and GSNO additive-cultures, respectively. However, 3D
cultures modestly increased matrix HA yields, in the presence or absence of GSNO (2% and 1.9%, respectively).
3.7. LOX enzyme activity
While GSNO addition to 2D cultures did not induce a signiﬁcant
change in LOX activity within cell matrix, it induced a 2.55-fold increase within 3D cultures (Fig. 3A; p < 0.01). LOX activity in matrix
within 3D cultures was signiﬁcantly higher (2.2-fold; p < 0.01) than
that in 2D cultures. LOX activity within pooled media from 3D cultures
was 13.5-fold higher than that in 2D cultures in the absence of GSNO.
Although adding GSNO to 3D cultures did not enhance LOX activity
compared to controls, it signiﬁcantly increased LOX activity within 2D
cultures (14.9-fold; p < 0.01).
3.8. Desmosine crosslink density
In healthy SMC cultures (Fig. 3B), desmosine levels were higher in
2D cultures than in 3D cultures (p < 0.01), and GSNO oﬀered no additional beneﬁt in both 2D and 3D cultures. However, in AAA-SMC
cultures, desmosine levels were signiﬁcantly higher in controls compared to GSNO-receiving cultures (p < 0.01), in both 2D and 3D. The
basal levels of desmosine by AAA-SMCs remained unaltered in both 3D
and 2D cultures. Finally, signiﬁcant diﬀerence in desmosine levels were
noted between healthy and AAA derived SMCs, in 3D cultures receiving

Table 2
Amounts of various proteins deposited in cell matrix or released into pooled media by healthy and AAA human aortic SMCs, per cell, over a 21-day period, within 2D
or 3D cultures, in the presence or absence of 100 nM GSNO. Data shown here represents the average of at least n = 6/case. Data for the healthy Hu-SMCs were from
our previous publication [22].
GSNO
dose
(nM)

3D cultures
3D cultures
2D cultures

Healthy
Hu-SMCs
Hu-AAASMCs
Hu-AAASMCs

0
100
0
100
0
100

Fold-increase in
proliferation,
compared to initial
seeding

3.2
2.03
2.05
1.3
2.8
2.1

Total protein
amounts (μg)

Elastin (ng)

Cell
matrix

Pooled
media

Cell matrix

Pooled
media

Cell matrix

Pooled
media

Cell matrix

Pooled
media

Cell
matrix

Pooled
media

0.13
0.12
0.27
0.83
0.016
0.042

2.02
3.12
37.9
52.7
16.8
34.6

ND
1.31
< 0.01
< 0.01
< 0.01
< 0.01

7.06
29.9
0.17
0.26
0.15
0.177

ND
0.49
< 0.01
< 0.01
< 0.01
< 0.01

16.7
7.08
0.036
0.063
0.015
0.034

0.21
0.5
0.57
0.77
0.36
0.51

2.07
3.2
27.6
40.7
22.8
29.7

69
370
0.1
0.27
0.02
0.03

70
1610
2.76
3.1
0.18
2.5

ND: Not detectable within assay limits (i.e., < 1 pg/cell amounts).

sGAGs (ng)

HA (pg)

LOX functional
activity (pM)

Fig. 3. (A) Fold-changes in LOX enzyme functional
activity within cell matrix and pooled media of AAASMC cultures, quantiﬁed using an Amplex Red®
ﬂuorometric assay and quantiﬁed per cell. Cells were
exposed to 100 nM GSNO while controls received no
GSNO. The absolute amounts of LOX functional activity per cell were listed in Table 2 for baseline
purposes. (B) Desmosine levels in pooled media
collected from 2D/3D Hu-SMCs or AAA-SMC cultures, over the 21-day period, in the presence or
absence of GSNO. (C) iNOS protein expression was
quantiﬁed from Western blot analysis. Representative bands are shown in the insert for comparison. iNOS protein expression by AAA-SMC cultures was normalized to that in 2D GSNO-free
cultures of healthy SMCs. (D) Similarly, the release
of TIMP-1 into pooled media was quantiﬁed using a
TIMP-1 ELISA assay. GSNO (0 or 100 nM) was supplemented to AAA-SMC cultures in 2D or 3D cultures
over 21 days. Data were analyzed using one-way
ANOVA followed by Tukey's HSD post-hoc testing,
assuming unequal variance and diﬀerences deemed
signiﬁcant for p < 0.05. Data shown represent
mean ± standard error of quantiﬁed data and normalized to cell count within respective cases (n = 6
per condition). (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to
the Web version of this article.)

no GSNO (p < 0.001).
3.9. iNOS expression and TIMP-1 release
To test if exogenously-delivered NO inﬂuenced iNOS protein expression in AAA-SMC cultures, Western blot analysis was performed
(Fig. 3C; bands in insert). The basal level of iNOS expression (2D control cultures) was signiﬁcantly higher in AAA-SMCs compared to
healthy counterparts (p < 0.05). It was found that GSNO addition to
2D cultures signiﬁcantly promoted iNOS protein expression in healthy
SMCs, but not in 3D cultures. Expression of iNOS by AAA-SMCs, on the
other hand, was not modiﬁed by 2D or 3D cultures, and/or by GSNO
addition.
No signiﬁcant diﬀerence in TIMP-1 release was noted between 2D
and 3D AAA-SMC cultures in controls (Fig. 3D). GSNO induced a 2.4fold increase in TIMP-1 release in 3D cultures. While the basal levels of
TIMP-1 release was signiﬁcantly lower in AAA-SMCs compared to adult
healthy aortic SMCs in 3D cultures [22], the levels were similar in the
presence of 100 nM GSNO.
3.10. Elastin, iNOS, LOX and ﬁbrillin gene expression
Elastin (ELN) gene expression in AAA-SMCs, both in 2D and 3D
cultures, in the presence or absence of NO cues, was signiﬁcantly lower
compared to healthy SMCs (Fig. 4A). Such inhibited elastin gene expression levels in AAA-SMCs, compared to healthy SMCs, was in
agreement with their respective protein expression levels of matrix
elastin (Table 2). Similarly, within AAA-SMCs, elastin gene expression
was signiﬁcantly lower in 2D compared to that in 3D, in agreement
with their protein expression levels. Surprisingly, elastin gene expression was signiﬁcantly lower after GSNO addition, in contrast to tropoelastin and matrix elastin produced by these cells (Fig. 2, C-D).
The iNOS gene expression of healthy and AAA-SMCs were similar in
2D and signiﬁcantly increased in 3D cultures for AAA-SMCs (Fig. 4A).
Adding GSNO had no signiﬁcant eﬀect on iNOS gene expression in
AAA-SMC cultures, suggesting that AAA-SMCs are sensitive to signaling
from exogenous NO cues, similar to their healthy counterparts. LOX
gene expression was signiﬁcantly higher (6–10 -fold in 2D and 3D

cultures, respectively) in AAA-SMCs compared to healthy SMCs, although adding GSNO suppressed such elevated levels (Fig. 4A), in
contrast with the LOX functional activity (Fig. 3A). The baseline levels
of ﬁbrillin-1 (FBN) gene in AAA-SMCs was signiﬁcantly higher compared to their healthy counterparts, although such expression levels
were signiﬁcantly downregulated in 2D AAA-SMC cultures with GSNO
addition (Fig. 4A).
3.11. Release of cytokines, chemokines, MMPs, and TIMPs
We quantiﬁed the baseline levels (2D - 0 nM) of cytokines, chemokines, MMPs and TIMPs released by healthy Hu-SMCs [Supplementary
Fig. 2 (A: < 10 pg/mL; C: < 250 pg/mL; E: < 40 ng/mL)] and adult
human AAA-SMCs [Supplementary Fig. 2 (B: < 10 pg/mL;
D: < 250 pg/mL; F: < 40 ng/mL)]. Their levels in 3D cultures, and in
the presence of 100 nM GSNO were also shown in respective panels.
The analytes released by SMCs were plotted on a log-scale using a
heatmap function (Fig. 4B). MMPs and TIMPs were the most highlyexpressed analytes compared to the cytokines (e.g., ILs). Beneﬁts of
GSNO delivery in healthy SMC cultures (both 2D and 3D), appeared
marginal with no signiﬁcant modulation in ILs and MMPs release but
signiﬁcant increase in TIMPs release. However, in 3D AAA-SMC cultures, GSNO suppressed the release of several analytes (e.g., IFN-γ,
MMPs-8, 9, 12, IL-8) compared to all other conditions, and some analytes were undetectable in most conditions (IL-1β and TNF-α). A tenfold increase in IL-6 release by AAA-SMCs was found compared to
healthy counterparts. Variations in analyte concentrations were observed across samples cultured in 2D vs. 3D environments; for instance,
SMCs in 2D cultures had higher concentrations of MMP-2, MMP-12,
TIMP-2, TIMP-3, and MCP-1, in both healthy and AAA-SMC cultures. In
general, cytokine and MMPs production in both cell types appeared to
be regulated by GSNO presence as well as culture substrate (2D vs. 3D).
3.12. Immunoﬂuorescence labeling of matrix proteins
AAA-SMCs deposited detectable matrix elastin and ﬁbulins-4 and 5
within 2D cultures over the 21-day period within control cultures
(Fig. 5). However, ﬁbrillin-1, critical for matrix elastin coacervation

Fig. 4. (A) Lavik method (ΔΔCt method) was used for relative quantiﬁcation of the fold changes in ELN, iNOS, LOX, and FBN genes in AAA-SMCs, after addition of
GSNO (0 or 100 nM) within 2D or 3D cultures for 21 days. The gene expressions obtained from qRT-PCR analysis within AAA-SMCs were ﬁrst normalized to
housekeeping gene (18S) expression within respective cultures, and further normalized to respective gene expressions within healthy Hu-SMCs cultured under similar
conditions. Data were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and diﬀerences deemed signiﬁcant for
p < 0.05. Data shown represent mean ± standard error (n = 6 independent data points per condition). (B) Heat map showing the amounts of cytokines, chemokines, and MMPs/TIMPs released by healthy and AAA SMCs, in 2D and 3D cultures, in the presence or absence of 100 nM GSNO, as measured using laser bead
immunoassay.

and crosslinking, was undetectable around the periphery of most cells.
GSNO promoted deposition of matrix elastin, ﬁbrillin-1 and ﬁbulins-4,
5, compared to controls.

3.13. Cell mechanics using AFM
Single cell nanoindentation measurements were obtained to quantify the elastic modulus (E) of live SMCs under diﬀerent culture conditions (Fig. 6; Supplementary Fig. 3). Representative phase-contrast

images (Supplementary Fig. 3), heat maps of elastic moduli (Fig. 6A),
and force-indentation curves (Fig. 6B) were shown for healthy and AAA
SMCs, in the presence or absence of GSNO. The average modulus of
elasticity for AAA-SMCs (17.41 ± 0.34 kPa) was signiﬁcantly higher
(1.6-fold; p < 0.001) than for healthy SMCs (10.42 ± 0.29 kPa), indicating an increase of stiﬀness in AAA-SMCs (Fig. 6C). Upon exposure
to GSNO, the average modulus of elasticity for healthy SMCs decreased
by 1.3-fold (healthy SMCs: 8.67 ± 0.25 kPa, p < 0.05; AAA-SMCs:
13.03 ± 0.35 kPa, p < 0.05). Cell roughness measurements showed

Fig. 5. Representative immunoﬂuorescence images of AAA-SMC layers in 2D cultures, with or without GSNO, stained with respective primary antibodies for elastin,
ﬁbrillin-1, ﬁbulin-4 and ﬁbulin-5, and counterstained with DAPI for cell nuclei. A signiﬁcant increase in the expression of all the proteins was noted in the presence of
100 nM GSNO. Scale bar: 100 μm. For each treatment condition, at least three independent cell layers were imaged, with six random regions captured in each cell
layer.

that AAA-SMCs were smoother than Hu-SMCs (Fig. 6D). GSNO addition
signiﬁcantly increased cell surface roughness in Hu-SMCs (p < 0.01),
and nearly doubled the roughness in AAA-SMCs, compared to respective controls. In the presence of GSNO, Hu-SMCs and AAA-SMCs
had no signiﬁcant diﬀerences in their surface roughness.
4. Discussion
In this study, we compared the diﬀerences and behaviors of human
aneurysmal SMCs and their healthy counterparts regarding cell proliferation, phenotypic and gene expression, transcriptomic analyses,
immunoﬂuorescence imaging, biomechanical characteristics, and their
response to exogenously-delivered NO cues, as a therapeutic AAA

treatment.
Prior studies reported that adult human AAA-SMCs proliferated 4fold over 16 days [37], 5-fold over 21 days [38], or doubled every 5.3
days [39] in 2D cultures, which is signiﬁcantly higher than that noted
in our study. AAA-SMCs proliferated signiﬁcantly slower compared to
their healthy counterparts (Table 2), possibly due to diseased nature
and/or minor diﬀerences in the phenotype between donors. AAA-SMCs
synthesized and deposited more proteins in 3D cultures compared to
the healthy aortic SMCs. Our results highlight the increased ability of
aortic SMCs to proliferate, migrate and deposit ECM under diseased
vascular conditions [40].
Despite the prominent role of elastin in aortic tissue homeostasis
maintenance, quantiﬁcation of elastin synthesized by human AAA-

Fig. 6. (A) Representative force maps of healthy Hu-SMCs (left panels) and AAA-SMCs (right panels) treated with 100 nM GSNO (lower panels). Background from
Petri dish was subtracted in these images. Representative force-indentation curves (B) and average Young's Modulus (C) of these cells cultured on 2D substrates, in
the presence or absence of 100 nM GSNO. The black dotted lines in (C) represent the arithmetic averages in respective cases, i.e., 10.33 ± 0.2624 KPa for untreated
Hu-SMCs (n = 605), 8.674 ± 0.2491 KPa for Hu-SMCs receiving GSNO (n = 550), 17.41 ± 0.3405 KPa for untreated AAA-SMCs (n = 524), and
13.03 ± 0.3498 KPa for AAA-SMCs receiving GSNO (n = 469). (D) The surface roughness parameters Rq and Ra in Hu-SMCs and AAA-SMCs, in the presence of
absence of GSNO. Data were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and diﬀerences deemed
signiﬁcant for p < 0.05. Data shown represent mean ± standard error (n = 6 independent data points per condition).

SMCs has received less attention. Tropoelastin, the precursor molecule
to elastin, is encoded by a single copy of ELN gene in SMCs and ﬁbroblasts. Tropoelastin amounts in human AAA extracts was reported to
be 5-fold higher than that within normal human aortic tissues [21]. Our
current study suggests that healthy Hu-SMCs produce higher amounts
of tropoelastin and matrix elastin compared to their AAA counterparts.
Adult human AAA-SMCs were shown to release ~10 pg of tropoelastin
and deposited 0.02 pg of matrix elastin per cell in 2D cultures, in the
absence of any external cues [38]. These amounts were signiﬁcantly
lower than what we observed, despite similarities in donor age, disease
phenotype and culture duration. Numerous studies have shown that the
signiﬁcant changes in elastin protein within AAA ECM might be due to
a related change in the gene expression levels [41,42]. Similar to our
observations here, a down-regulation in elastin gene in AAA tissues was
reported in a porcine model of induced AAA, compared to healthy
counterparts [43].
Adult human AAA-SMCs in 2D cultures release signiﬁcantly higher
levels of GAGs (e.g., versican, perlecan, heparan sulfate, biglycans)
compared to healthy aortic SMCs [44]. Although the various types of
sGAGs released by AAA-SMCs were not individually identiﬁed in our
study, we quantiﬁed the absolute amount of overall GAGs production
by AAA-SMCs and found multifold increases in HA release into pooled
media and deposition into matrix within AAA-SMC cultures. The
combined amount of elastin and GAGs, in both pooled media and cell
matrix, constitute a small fraction of the total matrix, suggesting that in
addition to elastin and GAGs, numerous other proteins such as collagens and proteoglycans, might have been released and deposited by
AAA-SMCs within 2D and 3D cultures.
Such deposited elastin precursors are crosslinked in the presence of
LOX enzyme, resulting in the formation of desmosine and isodesmosine
linkages between lysine molecules on elastin molecules [45]. Thus, the
ﬁnal crosslinked elastic ﬁbers typically have a microﬁbril sheath surrounding the core elastin molecules. Additional stimulation such as
alternate scaﬀold design, elastogenic scaﬀold material, exogenous LOX,
and mechanical stimuli might be necessary to coax the AAA-SMCs to
enhance matrix elastin yields. Although it is interesting to note that
AAA-SMCs produce LOX which is functionally active, the levels of LOX
functional activity within AAA-SMC cultures are at least two orders of
magnitude lower than that quantiﬁed within healthy SMC cultures
(Table 2), per cell. This diﬀerence might be due to the phenotypic
diﬀerences between healthy versus AAA cells. Studies have shown that
in addition to regulating vascular SMC phenotype (proliferation, migration), LOX also plays a primary role in ECM crosslinking such as
collagens, elastin and GAGs [46]. However, under diseased conditions
such as aneurysms, characterized by remarkable degradation and ECM
remodeling, LOX activity and expression is signiﬁcantly reduced. While
it is not clear whether reduction in LOX levels contribute to the onset of
the pathogenesis of these diseases or vice versa, numerous AAA-induced
animal models demonstrate strong correlation between LOX expression
reduction and disease progression [47]. Desmosine levels were detectable even in AAA-SMC cultures attesting to their ability to release
components critical for crosslinked elastin deposition, although GSNO
presence did not further stimulate these levels. Prior studies have
shown that desmosine levels in healthy human arterial tissues were at
least 9-fold higher than that in AAA segments [21], and reduced desmosine levels were reported in dissecting AAAs [48], suggesting the
reason for diminished levels of mature, crosslinked elastin in AAA tissues.
Although vascular NO plays an important role in regulating SMC
functions such as vasodilation, survival, gene regulation, and quiescence phenotype, the harmful role of higher NO levels in the pathogenesis of aneurysms has been documented [49–51]. Speciﬁcally, iNOSstimulated NO release from vascular SMCs was shown to participate in
elastin degradation and disruption of vascular ECM [52]. Our observations agree with previous reports that experimental or human
AAA-derived tissues had higher iNOS levels compared to control tissues

where iNOS could barely be detected [50,53]. TIMPs-1, 2 regulate ECM
remodeling in vasculature by controlling the levels and activity of
MMPs. In agreement with our results, no signiﬁcant diﬀerences in
TIMP-1 levels (Western blotting) within tissue sections isolated from
AAA patients and their healthy counterparts were observed [54].
Localized inﬂammation contributes to weakening of aorta due to
imbalances in ECM levels [55]. This has prompted research focused on
regulating the production of inﬂammatory molecules as a therapeutic
intervention in lieu of invasive surgical approaches [56]. The concentrations noted for MMPs/TIMPs in our study broadly falls in the
range reported by others and our previous work [22,37]. Given the
apparent diﬀerences in cytokine production between AAA and healthy
SMCs, our data supports the prevailing notion that cytokine stimulation
via paracrine or autocrine signaling may in turn modulate MMP activation [57]. Although it has been suggested that NO can inﬂuence the
production of some cytokines and chemokines [58], we did not see any
diﬀerences. In summary, our data is consistent with the inﬂammatory
patterns seen in AAA subjects and suggests that NO presence modulates
MMP production in a potentially therapeutic manner.
In addition to alterations in composition and functionality of vascular endothelium and ECM, changes in cell stiﬀness might also contribute to vascular tissue stiﬀness in AAAs, atherosclerosis and hypertensive conditions. The stiﬀness (~30 kPa) of hypertensive aortaderived SMCs, as measured by AFM nano-indentation, was reported to
be two-fold higher than that of normal aorta (~14 kPa), and such
stiﬀness was mediated by cytoskeletal proteins [59]. Vascular SMCs
from old male monkeys exhibited much higher stiﬀness than their
younger counterparts (42 kPa vs. 13 kPa) [60]. The elastic modulus of
primary adult male rat arteriole-derived SMCs (~13.5 kPa) decreased
by 38% upon exposure to NO donor PANOate, most likely due to remodeling of actin cytoskeleton network [61]. Marfan vascular SMCs
were two-fold stiﬀer than healthy human SMCs, as measured by AFM,
most likely due to higher focal adhesion kinase protein and actin stress
ﬁbers expression [62]. Here, we report for the ﬁrst time on the stiﬀness
and surface roughness of human aortic SMCs from healthy and AAA
tissues, using AFM nano-indentation of live cells. Our results show that
(i) elastic modulus of healthy Hu-SMCs is lower than that in rats and
monkeys; (ii) human AAA-SMCs have higher stiﬀness and lower surface
roughness compared to healthy Hu-SMCs; and (iii) human AAA-SMCs
had signiﬁcantly lower stiﬀness compared to hypertensive rat SMCs or
aged monkey SMCs.
Our results support our hypothesis that AAA-SMCs do respond to
exogenous NO cues to modulate cell proliferation and protein synthesis
in 3D cultures. We have recently shown that healthy Hu-SMCs produced
signiﬁcantly higher amounts of tropoelastin and matrix elastin in the
presence of 100 nM GSNO, and that an optimal 100 nM GSNO promoted
sGAG deposition in matrix layers but not their release into the pooled
media, within 3D Hu-SMC cultures [22]. Our results along with pertinent literature suggest that exogenously-delivered NO donors (e.g.,
GNSO) release NO and other reaction products which stimulate iNOS
expression and endogenous NO release in healthy or aneurysmal SMC
cultures (Fig. 7). Such endogenous NO upregulates cGMP and thereby
protein kinase G (PKG) activation in SMCs [23,63], which in turn induce cell relaxation (i.e., low stiﬀness) [64], suppress proliferation
[65], and stimulate elastic matrix synthesis [23]. This cascade of events
might contribute to enhanced SMC phenotype leading to improvement
in vascular tone and compliance in vivo, desired from a therapeutic
standpoint.
An increase in LOX functional activity within 3D AAA-SMC cultures
in GSNO presence (Fig. 3), and signiﬁcantly higher deposition of ﬁbrillar forms of elastic matrix-associated proteins such as ﬁbrillin-1, and
ﬁbulins- 4, 5 (Fig. 5), is highly encouraging for therapeutic tissue engineering and in situ elastin regeneration. Increased levels of LOX
functional activity by exogenous GSNO might partially explain the increases in matrix elastin, GAGs, and tropoelastin in 3D AAA-SMC cultures. Similar increases in tropoelastin but not desmosine levels by

matrix and associated proteins synthesis and deposition, release of cytokines/chemokines/MMPs/TIMPs, changes in gene expression of
elastogenic markers, and stiﬀness and roughness. We demonstrated that
exogenously delivering NO via GSNO oﬀers an eﬀective strategy to
enhance AAA-SMC functionality. Our current studies are geared towards validating these phenotypic, genetic expression, and biomechanical outcomes in multiple patient-derived AAA and healthy SMCs.
Nevertheless, these results help in designing tissue engineering and
regenerative medicine-based approaches, consisting of 3D scaﬀolds and
localized drug delivery options, speciﬁcally for in situ elastin regeneration and remodeling to arrest aneurysm progression.
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Fig. 7. Schematic of the hypothesized mechanism by which exogenously-delivered nitric oxide (NO) donors such as GSNO ultimately inﬂuence smooth
muscle cell (SMC) phenotype and genotype in both healthy and aneurysmal
aorta. Sequentially, the NO released by donors upregulates iNOS gene expression and manifests as endogenous NO release, which in turn increases cyclic
guanosine monophosphate (cGMP) and protein kinase G (PKG) expression,
thereby enhancing cell relaxation, suppressing proliferation, and promoting
elastic matrix synthesis. These together contribute to heightened contractile
SMC phenotype and improved vasculature tone and compliance in vivo. Here E
refers to elastic modulus, an estimate of the cell stiﬀness.

human and rat AA-SMCs were reported by others [21,66]. Higher
amounts of GSNO (> 100 nM) could possibly elevate desmosine levels
in 3D AAA-SMC cultures, which further enhances elastin crosslinking
and maturation.
The increased levels of TIMP-1 in AAA-SMC 3D cultures in the
presence of GSNO is encouraging in modulating further degradation of
vascular ECM by MMPs under diseased conditions. GSNO induced signiﬁcant increases in matrix elastin deposition in 3D cultures and reduced MMP-9 concentration by over 50% in all cases (2D/3D AAA-SMC
cultures), compared to healthy controls. Given that the upregulation of
MMP-9 is linked to the degradation of the aortic ECM, our results are
encouraging as they suggest a therapeutic beneﬁt in the supplementation of exogenous NO [67]. Similar trend was noted for MMP-2 in
nearly all cases (excluding 3D AAA-SMC cultures). Similar patterns in
MMP downregulation were observed in eNOS gene–transfected cells
[68], and it has been suggested this pathway is regulated by guanylylcyclase dependent and independent pathways [69]. NO appeared to
have little eﬀect on TIMPs release across most cases. In agreement with
literature, we noticed signiﬁcantly higher IL-6 levels by AAA-SMCs.
And ﬁnally, delivering exogenous NO signiﬁcantly lessened AAA-SMC
stiﬀness and enhanced surface roughness, possibly via modulation of
cytoskeletal and surface proteins, respectively. We postulate that
changes in stiﬀness beginning at single cell level might contribute to
changes in vascular tone and functionality of aneurysmal vessels and
delivering GSNO could be explored as a therapeutic strategy. Taken
together, results conﬁrm our hypothesis that exogenous NO delivery to
AAA-SMCs might help to promote protein synthesis, release and deposition within 3D cultures, in addition to regulating their proliferation.
In conclusion, we established the baseline diﬀerences between adult
human AAA and healthy SMCs, in terms of their size, proliferation,
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